Journal of Cataract & Refractive Surgery
Volume 34, Issue 9 , Pages 1460-1467 , September 2008

Third- and fourth-generation fluoroquinolones: Retrospective comparison of endophthalmitis after cataract surgery performed over 10 years

,Accepted 9 May 2008.

References 

  1. Powe NR, Schein OD, Gieser SC, Tielsch JM, Luthra R, Javitt J, et al. Synthesis of the literature on visual acuity and complications following cataract extraction with intraocular lens implantation; the Cataract Patient Outcome Research Team. Arch Ophthalmol. 1994;112:239–252erratum, 889
  2. Jensen MK, Fiscella RG, Crandall AS, Moshifar M, Mooney B, Wallin T, et al. A retrospective study of endophthalmitis rates comparing quinolone antibiotics. Am J Ophthalmol. 2005;139:141–148
  3. West ES, Behrens A, McDonnell PJ, Tielsch JM, Schein OD. The incidence of endophthalmitis after cataract surgery among the U.S. Medicare population increased between 1994 and 2001. Ophthalmology. 2005;112:1388–1394
  4. Taban M, Behrens A, Newcomb RL, Nobe MY, Saedi G, Sweet PM, et al. Acute endophthalmitis following cataract surgery; a systematic review of the literature. Arch Ophthalmol. 2005;123:613–620
  5. Jensen MK, Fiscella RG, Lewis CC. Using an infection-reporting database to improve outcomes in cataract-surgery patients. Am J Health Syst Pharm. 2004;61:198–201
  6. Taban M, Rao B, Reznik J, Zhang J, Chen Z, McDonnell PJ. Dynamic morphology of sutureless cataract wounds—effect of incision angle and location. Surv Ophthalmol. 2004;49(suppl 2):S62–S72
  7. Ciulla TA, Starr MB, Masket S. Bacterial endophthalmitis prophylaxis for cataract surgery. Ophthalmology. 2002;109:13–26
  8. Ta CN. Topical antibiotic prophylaxis in intraocular injections. Arch Ophthalmol. 2007;125:972–974
  9. Deramo VA, Lai JC, Fastenberg DM, Udell IJ. Acute endophthalmitis in eyes treated prophylactically with gatifloxacin and moxifloxacin. Am J Ophthalmol. 2006;142:721–725
  10. Starr MB. A retrospective study of endophthalmitis rates comparing quinolone antibiotics. [letter] Am J Ophthalmol. 2005;140:769–770
  11. Thoms SS, Musch DC, Soong HK. Postoperative endophthalmitis associated with sutured versus unsutured clear corneal cataract incisions. Br J Ophthalmol. 2007;91:728–730
  12. Lai WW, Chu KO, Chan KP, Choy KW, Wang CC, Tsang CW, et al. Differential aqueous and vitreous concentrations of moxifloxacin and ofloxacin after topical administration one hour before vitrectomy. Am J Ophthalmol. 2007;144:315–318
  13. Hwang DG. Fluoroquinolone resistance in ophthalmology and the potential roles for newer ophthalmic fluoroquinolones. Surv Ophthalmol. 2004;49(suppl 2):S79–S83
  14. Smith A, Pennefather PM, Kaye SB, Hart CA. Fluoroquinolones: place in ocular therapy. Drugs. 2001;61:747–761
  15. Kowalski R, Khaliwal D, Karenchak L, Romanowski EG, Mah FS, Ritterband DC, et al. Gatifloxacin and moxifloxacin: an in vitro susceptibility comparison to levofloxacin, ciprofloxacin, and ofloxacin using bacterial keratitis isolates. Am J Ophthalmol. 2003;136:500–505
  16. Mather R, Karenchak LM, Romanowski EG, Kowalski RP. Fourth generation fluoroquinolones: new weapons in the arsenal of ophthalmic antibiotics. Am J Ophthalmol. 2002;133:463–466
  17. Mah FS. New antibiotics for bacterial infections. Ophthalmol Clin North Am. 2003;16(1):11–27
  18. ESCRS Endophthalmitis Study Group. Prophylaxis of postoperative endophthalmitis following cataract surgery: results of the ESCRS multicenter study and identification of risk factors. J Cataract Refract Surg. 2007;33:978–988
  19. O'Brien TP, Arshinoff SA, Mah FS. Perspectives on antibiotics for postoperative endophthalmitis prophylaxis: potential role of moxifloxacin. J Cataract Refract Surg. 2007;33:1790–1800
  20. Kunimoto DY, Sharma S, Garg P, Rao GN. In vitro susceptibility of bacterial keratitis pathogens to ciprofloxacin; emerging resistance. Ophthalmology. 1999;106:80–85
  21. Goldstein MH, Kowalski RP, Gordon YJ. Emerging fluoroquinolone resistance in bacterial keratitis; a 5-year review. Ophthalmology. 1999;106:1313–1318
  22. Garg P, Sharma S, Rao GN. Ciprofloxacin-resistant Pseudomonas keratitis. Ophthalmology. 1999;106:1319–1323
  23. Chaudhry NA, Flynn HW, Murray TG, Tabandeh H, Mello MO, Miller D. Emerging ciprofloxacin-resistant Pseudomonas aeruginosa. Am J Ophthalmol. 1999;128:509–510
  24. Bower KS, Kowalski RP, Gordon YJ. Fluoroquinolones in the treatment of bacterial keratitis. Am J Ophthalmol. 1996;121:712–715
  25. Alexandrakis G, Alfonso EC, Miller D. Shifting trends in bacterial keratitis in South Florida and emerging resistance to fluoroquinolones. Ophthalmology. 2000;107:1497–1502
  26. Marangon FB, Miller D, Muallem MS, Romano AC, Alfonso EC. Ciprofloxacin and levofloxacin resistance among methicillin-sensitive Staphylococcus aureus isolates from keratitis and conjunctivitis. Am J Ophthalmol. 2004;137:453–458
  27. Scheld WM. Maintaining fluoroquinolone class efficacy: review of influencing factors. [editorial] Emerg Infect Dis. 2003;9:1–9Available at: http://www.cdc.gov/ncidod/eid/vol9no1/02-0277.htmAccessed June 12, 2008
  28. Kowalski RP, Dhaliwal D. Ocular bacterial infections: current and future treatment options. Expert Rev Anti Infect Ther. 2005;3:131–139

 No author has a financial or proprietary interest in any material or method mentioned.

PII: S0886-3350(08)00641-X

doi: 10.1016/j.jcrs.2008.05.045

Journal of Cataract & Refractive Surgery
Volume 34, Issue 9 , Pages 1460-1467 , September 2008

Article Tools

* Image Usage & Resolution